Wuestemeyer Henrike, Sauerwein Wolfgang, Meller Daniel, Chauvel Pierre, Schueler Andreas, Steuhl Klaus-Peter, Bornfeld Norbert, Anastassiou Gerasimos
Department of Ophthalmology, University of Essen, Hufelandstr. 52, 45122, Essen, Germany.
Graefes Arch Clin Exp Ophthalmol. 2006 Apr;244(4):438-46. doi: 10.1007/s00417-005-0093-5. Epub 2005 Aug 23.
Diffuse and multifocal patterns of conjunctival melanoma may not be treatable with standard eye-sparing methods. The purpose of this study was to evaluate the usefulness of proton beam radiation therapy as an alternative to exenteration.
Twenty patients with extended conjunctival melanoma were treated by proton beam irradiation. Most cases were T3 tumours which were not accessible to brachytherapy due to their extension, localisation with fornical or caruncular involvement. Only 2 patients had a tumour limited to the bulbar conjunctiva. Both were recurrent tumours with multiple lesions. Sixteen cases were recurrences after various pre-treatments. The area of the conjunctiva which was suspected to have microscopic disease was treated by 31 Gy in 6 fractions. The "high risk" areas with a clinically detectable tumour (primary target volume) were treated by an additional boost using a smaller beam size and applying 2 fractions up to 45 Gy. An individually shaped compensator was brought into the beam to modify the range of the protons so that the eye was irradiated only at a depth of 2 mm.
The mean follow-up time was 38.1+/-26.6 months (median 34 months). Recurrent disease occurred in 6 cases (30%); 2 of them outside the irradiated volume, 3 within the target volume treated by 31 Gy, and just one in the primary target volume treated by 45 Gy. An exenteration followed only in two patients (10%). 6 patients (30%) suffered from metastatic disease and 4 (20%) of them have died by now. During follow up we found no statistically significant association between the occurrence of local recurrence after proton radiotherapy and the development of metastases. Best corrected visual acuity remained stable in 12 cases (60%); in 14 patients the best corrected visual acuity was 0.25 or better. A sicca-syndrome developed in 19/20 patients. However, only 10/20 patients used artificial tears more than 5x/d. A focal cataract developed in 7 patients (35%). There was eyelash loss in the area of irradiated eyelids. In 4 cases a limbal stem cell deficiency occurred with the consequence of corneal vascularisation.
Proton radiotherapy may serve as an alternative to exenteration in case of T3 and diffuse T1 or T2 conjunctival melanomas.
结膜黑色素瘤的弥漫性和多灶性模式可能无法通过标准的保留眼球方法进行治疗。本研究的目的是评估质子束放射治疗作为眶内容剜除术替代方法的有效性。
20例结膜黑色素瘤扩展患者接受了质子束照射治疗。大多数病例为T3肿瘤,由于其扩展、累及穹窿部或泪阜的定位,近距离放射治疗无法实施。只有2例患者的肿瘤局限于球结膜。两者均为有多个病灶的复发性肿瘤。16例为各种预处理后的复发。怀疑有微小病变的结膜区域分6次给予31 Gy治疗。临床可检测到肿瘤的“高危”区域(主要靶体积)通过使用较小射野大小并追加2次分割至45 Gy进行额外的推量照射。在射束中放入一个个体化塑形的补偿器来改变质子的射程,以便仅在2 mm深度处照射眼球。
平均随访时间为38.1±26.6个月(中位数34个月)。6例(30%)出现疾病复发;其中2例在照射野之外,3例在接受31 Gy治疗的靶体积内,仅1例在接受45 Gy治疗的主要靶体积内。仅2例患者(10%)随后接受了眶内容剜除术。6例患者(30%)发生转移性疾病,其中4例(20%)目前已经死亡。在随访期间,我们发现质子放疗后局部复发的发生与转移的发展之间无统计学显著关联。12例患者(60%)的最佳矫正视力保持稳定;14例患者的最佳矫正视力为0.25或更好。19/20例患者出现干眼综合征。然而,只有10/20例患者每天使用人工泪液超过5次。7例患者(35%)发生局灶性白内障。照射眼睑区域出现睫毛脱落。4例患者发生角膜缘干细胞缺乏并导致角膜血管化。
对于T3以及弥漫性T1或T2结膜黑色素瘤,质子放疗可作为眶内容剜除术的替代方法。